We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vela Technologies Plc | LSE:VELA | London | Ordinary Share | GB00BYZ9XC29 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.012 | 0.011 | 0.013 | 0.012 | 0.012 | 0.012 | 26,317,159 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 0 | -378k | 0.0000 | N/A | 1.63M |
TIDMVELA
RNS Number : 8188F
Vela Technologies PLC
09 November 2022
9 November 2022
Vela Technologies plc
("Vela" or "the Company")
Update re. AZD1656
The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes the announcement made yesterday evening by Conduit Pharmaceuticals Limited ("Conduit") that it intends to become a publicly traded company on NASDAQ in the USA via a merger with Murphy Cannon Acquisition Corp. ("Murphy"), a NASDAQ-listed special purpose acquisition company.
Vela holds an economic interest in the commercialisation of a particular application of AZD1656, one of the assets of Conduit. Details of Vela's interest in AZD1656 were set out in the announcement published by Vela on 20 October 2020.
A copy of the announcement can be found at:
Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp. (accesswire.com)
The salient points of the announcement are as follows:
-- Conduit and Murphy have entered into a definitive business combination agreement.
-- The business combination is expected to provide Conduit with access to the public equity markets, which the parties believe will accelerate development of Conduit's autoimmune disease and idiopathic male infertility pipeline.
-- The business combination is expected to close in the first quarter of 2023.
-- The transaction is expected to deliver cash proceeds of around $149.65 million to Conduit (assuming no redemptions) to fund Conduit's clinical development programmes.
Further information on Conduit, including details on its relationship and partnership with St. George Street Capital, can be found in this presentation which was published as an SEC filing yesterday evening: https://www.sec.gov/Archives/edgar/data/1896212/000149315222030986/ex99-2.htm
For further information, please contact:
Vela Technologies plc Tel: +44 (0) 7410886830 Brent Fitzpatrick, Non-Executive Chairman James Normand, Executive Director Allenby Capital Limited (Nominated Adviser) Tel: +44 (0) 20 3328 5656 Nick Athanas / Piers Shimwell Peterhouse Capital Limited (Broker) Tel: +44 (0) 20 7469 0930 Lucy Williams / Duncan Vasey / Eran Zucker / Lauren Riley Novus Communications (PR and IR Adviser) Tel: +44 (0) 20 7448 9839 Alan Green / Jacqueline Briscoe
About Vela Technologies
Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
UPDVKLBBLFLEFBD
(END) Dow Jones Newswires
November 09, 2022 04:00 ET (09:00 GMT)
1 Year Vela Technologies Chart |
1 Month Vela Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions